Shannon Harville, APRN
Adult Health · Orlando, FLNPI 1659904449
Payments from drug & device makers
Across 96 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$246
- Cequr Corporation$236
- Sanofi-aventis U.S. LLC$227
- Amgen$191
- Lilly USA, LLC$179
- Medtronic$162
- plus $975 from 22 others
What the payments were for
- Food & beverage$2,18299%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 11 | $246 |
| Cequr Corporation | 1 | $236 |
| Sanofi-aventis U.S. LLC | 7 | $227 |
| Amgen | 11 | $191 |
| Lilly USA, LLC | 9 | $179 |
| Medtronic | 4 | $162 |
| AbbVie | 5 | $98 |
| Novartis | 5 | $91 |
| Madrigal Pharmaceuticals | 3 | $87 |
| Tandem Diabetes Care, Inc. | 11 | $84 |
| Recordati_rare_diseases_inc. | 4 | $74 |
| Sequel Med Tech, LLC | 2 | $60 |
| Radius Health, Inc. | 2 | $52 |
| BETA Bionics, Inc. | 2 | $50 |
| Corcept Therapeutics | 3 | $48 |
| Abbott | 2 | $43 |
| Amphastar Pharmaceuticals, Inc. | 2 | $41 |
| Bayer | 2 | $40 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| BD | 1 | $25 |
| Mannkind Corporation | 1 | $24 |
| Ascendis Pharma Endocrinology Inc | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$236
- MINIMED 780G$128
How this compares
$2,215 in reported general payments places this provider in the 75th percentile of 2,237 adult health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 159 | $202,837 |
| OzempicSemaglutide | 90 | $143,056 |
| JardianceEmpagliflozin | 78 | $105,519 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 50 | $65,088 |
| Tresiba Flextouch U-200Insulin Degludec | 39 | $49,214 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 51 | $40,255 |
| JanuviaSitagliptin Phosphate | 35 | $33,616 |
| FarxigaDapagliflozin Propanediol | 19 | $27,109 |
| Gvoke Hypopen 2-PackGlucagon | 35 | $21,858 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $21,779 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $17,169 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $16,638 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 29 | $13,524 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 55 | $8,472 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $7,755 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $179 | $202,837159 claims |
| Novo NordiskOzempic | $246 | $143,05690 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $18 | $122,68889 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $227 | $66,66362 claims |
| AbbVieSynthroid | $98 | $2,95534 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $14 | $2,482198 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,237 adult health providers in Florida.
Other adult health in Orlando
- Sita SwamyOrlando$49K
- Alejandro Dela CruzOrlando$44K
- Andreina NeallOrlando$16K
- Jessica SettineriOrlando$14K
- Kristen KessingerOrlando$13K
- Angelo LewisOrlando$12K
- Patricia PagnottaMaitland$441K
- Carly KoelschSarasota$265K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.